| Name | Title | Contact Details |
|---|
Finch Therapeutics is a clinical-stage microbiome therapeutics company leveraging its Human-First Discovery platform to develop a novel class of orally administered biological drugs. With the capabilities to develop both complete and targeted microbiome therapeutics, Finch is advancing a rich pipeline of candidates designed to address a wide range of unmet medical needs. Finch`s lead candidate, CP101, is in late-stage clinical development for recurrent C. difficile infection (CDI). In June 2020, Finch announced that CP101 met its primary efficacy endpoint in PRISM3, the first of two pivotal trials to support the development of CP101 for the prevention of recurrent CDI. Finch is also developing CP101 for chronic hepatitis B, and FIN-211 for autism spectrum disorder. In partnership with Takeda, Finch is advancing FIN-524 and FIN-525 for ulcerative colitis and Crohn`s disease, respectively.
Empowering the industry with the resources, expertise, and capital to help accelerate the advancement and adoption of cell and gene therapies.
Cardiff Oncology, Inc. is a clinical-stage biotechnology company with the singular mission of developing new treatment options for cancer patients in indications with the greatest medical need.
NextBio is a Santa Clara, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Pharmagen purifies and distributes safe drinking water through its chain of open water shops in Pakistan, where water contamination is a major challenge.